Antiviral Long Acting Drugs Landing in People Living With HIV

Study acronym: ALADDIN
StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Primary and study completion dates changed from estimate of Jul 1, 2026 to Jun 19, 2026
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 3 of 10 entries
    • Study description expanded, about 6 words
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Mar 1, 2026 to Jul 1, 2026
    • Study completion date: Nov 1, 2026 to Jul 1, 2026
    • Site details revised
    v3
  3. Phase: Phase 3 to Not applicable
    • Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 1, 2024 to Dec 2, 2024
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a monocentric, prospective, double-arm, randomized, open-label, implementation-effectiveness hybrid type III study aimed at comparing hospital-based and home-based administration of CAB LA + RPV LA treatment for HIV-1-infected patients. Study participants receiving IM CAB + RPV will complete various questionnaires and scales, including FIM, AIM, IAM, EQ-5D-5L, HAT-QoL, and HIVTSQ, throughout the study. HCPs will also complete FIM, AIM, IAM, and a Likert scale.
Trial Details
NCT Number NCT06468995
Lead Sponsor IRCCS San Raffaele
Collaborators: GlaxoSmithKline
Conditions
(from sponsor)		 HIV, Antiviral Agents
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov